GBIS - Global Innovative Systems, Inc. (fka GBIS)

[jmhollen]

For further information on the Enermed Therapy (TM), or to schedule an appointment in either our Vancouver, B.C. or Toronto, Ontario Treatment Centre, call our Toll Free Line 1-866-ENERMED

[timespastagain]

has anyone got any info on this stock. i understand that a new group is taken it over and putting a new deal into it. is that true.

[jmhollen]

Roller Coaster-ville, USA.............

GBIS 0.012 0.004 (25.00) 0.012 0.015 1,588,729

[jmhollen]

Looks like this one is going to be pretty volatile.

The bounce players should have fun.

John

[Mariner*]

10/4 JM, I do the same thing with the pinks...
Not a bad place to browse for some unheard of bargins and in this case you were right on.
I also had a friend that had a little "shock box" she wore for spasing out her back muscles after an accident as well. I seem to remember talking to a woman at a checkout counter that was wearing a wrist brace of some kind that had magnets enbedded into it for helping out her carpultunnel syndrom from too much repeditive action movements. So maybe there is a growing market for healing and electromagnetic applications.
M-

[jmhollen]

Note: The way I read it, there are 200MM shares authorized for GBIS, of which about 70MM have been spread around.

Two of the original Board members have quit. Each had 12MM shares, but apparently each of them shed 6MM to the new Board member. So the new guy has 12MM, leaving the two old guys with 6MM each to dump whenever their greed-factor is satisfied.

It's not a "..QBID..". But, you'll have to watch the trading pretty carefully.

http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fredirect.asp%3Ffilename%3D0001085037%252D03....

John

[jmhollen]

Thanks.

It must have caught my eye when I was scanning the Pinks one day.

The Enermed device seems to fall into the 'magnet therapy' category, like the disk magnets that are used in blankets, vests, or patches "..As Seen On TV..". I haven't done much DD on it, but it seemed worthy of a board.

I had a buddy in VA who got hurt in a car wreck, and wore a little "..shocking.." device on his belt that 'tweaked' his back muscles to avoid cramping and related pain. Mild electro-shock and magnetic flux therapy seems to be growing as an alternative to drugs or surgery.

Cheap enough to qualify as a Casino Money acquisition currently.

John

[Mariner*]

Nice board,Good info,Xcellent DD!!!
For some reason info on this stock is hard fought!!!
Good job John!!!

[jmhollen]

ENERMED RESEARCH REPORTS

Research to date has focused on the use of the Enermed for the treatment of two chronic conditions for which conventional medicine has no solutions: multiple sclerosis (MS) and migraine headaches.
The Company has undertaken a number of studies over the past five years.

Multiple Sclerosis (MS) Research
In 1996 we conducted a preliminary study of the effectiveness of the Enermed for the symptoms of MS. This research, conducted at the University of Washington in Seattle with partial funding from the National Institutes of Health (NIH), resulted in the following publications and presentations:


Richards TL, Lappin MS, Acosta-Urquidi J, Kraft GH, Heide AC, Lawrie FW, Merrill TE, Melton GB, Cunningham CA (1997). Double-blind study of pulsing magnetic field effects on multiple sclerosis. Journal of Alternative and Complementary Medicine, 3(1): 21-29.


Richards TL, Acosta-Urquidi J, Merrill TE, Kraft GH, Lappin MS, Lawrie FW (1997). Pulsing Magnetic Field Treatment Effects on Brain Electrical Activity in Multiple Sclerosis. Paper presented at the Consortium of Multiple Sclerosis Centers Conference, Systems of Care in Multiple Sclerosis, Sep 5-7, 1997, Calgary, Alberta Canada. Abstract appears in Multiple Sclerosis, 3(3), 1997.


Richards TL, Acosta-Urquidi J (1998). Pulsing Magnetic Field Effects on Brain Electrical Activity in Multiple Sclerosis in Biologic Effects of Light 1998: Proceedings of a Symposium, Basel, Switzerland November 1-3, 1998. Micheal F. Holick and Ernst G. Jung, Eds., Boston: Kluwer Academic Publishers, pp 337-342.

The promising results of the preliminary University of Washington study laid the groundwork for a larger, second study conducted at three research sites across the USA. This larger study, also a double-blind, placebo controlled trial, was generously supported by the Multiple Sclerosis Association of America, in Cherry Hill, New Jersey. Three publications have resulted from this effort, including a journal article currently undergoing peer review:


Lappin, MS (1998). Evaluation of a Pulsed Electromagnetic Therapy (Enermed) on Multiple Sclerosis (MS) Patient Symptoms and Quality of Life. Final Report submitted to the Multiple Sclerosis Association of America, Cherry Hill, NJ.


Richards TL, Lappin MS, Lawrie FW, Stegbauer KC (1998). Bioelectromagnetic applications for multiple sclerosis. Physical Medicine and Rehabilitation Clinics of North America, 9(3): 659-674.


Lappin MS, Lawrie FW, Richards TL, Kramer ED (2001). Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: A double-blind, placebo controlled trial. Under review.

Migraine Research

Our early research on the possible effectiveness of the Enermed for migraine headaches consisted of two patient surveys. Although the results are not as reliable as those obtainable from a carefully controlled clinical trial, they clearly demonstrated the promise of the Enermed as a preventive therapy for migraine sufferers.


Lappin, MS. (1995). Research on the Utility of the Enermed Device as Treatment for Migraines. (EMD Research Report #1). Energy Medicine Developments (North America) Inc., Vancouver, British Columbia.


Lappin MS. (1999). 1999 Enermed Patient Survey Results. (EMD Research Report #4). Energy Medicine Developments (North America) Inc., Vancouver, BC.

Clicking on the links below will take to a copy of these two reports:



#1 Research on the Utility of the Enermed Device as a Treatment for Migraines. April 1995

#4 1999 Enermed Patient Survey Results November 1999

We subsequently conducted a small, exploratory study of the effectiveness of the Enermed for women suffering from hormonally based migraines at clinical centers in Wisconsin and Virginia. What we learned paved the way for the development of a grant application we submitted to the NIH National Center for Complementary and Alternative Medicine.

This proposal was subsequently funded, allowing us to conduct our first controlled trial of the effectiveness of the Enermed for migraines.

Preliminary results were recently presented at a conference. A manuscript reporting the complete and final analyses is under preparation.



Lappin MS, Lawrie FW (2001). Preliminary Assessment of the Effects of a Pulsed Electromagnetic Field Therapy on Migraine Headaches. Presentation at the 9th Annual Society for Neuronal Regulation Conference, October 27-30, 2001, Monterey CA.
Abstract available at: http://www.snr-jnt.org/NewsPlus/2001/2001-Papers.htm

Other Applications

EMD is currently developing research protocols to capitalize on the growing interest in combining the Enermed therapy with neurofeedback in the treatment of depression. A pilot study presented at the 2000 Society for Neuronal Regulation conference suggested that this may be a very productive approach.


Baehr, E., Lappin, MS, Baehr, R., Matsumoto, MA. Neurofeedback and Pulsed Electromagnetic Therapy: A Match Made in Heaven. Paper presented at the Society for Neuronal Regulation Conference, September 2000, Minneapolis, MN. Abstract in the Journal of Neurotherapy, 4(4) 2001, 78-79. We expect to be able to report the results of additional studies in this area within the next year.



EMD Research Report #1
"Research on the Utility of the Enermed Device as a Treatment for Migraines"
prepared by Dr. Martha Lappin for Energy Medicine Developments (North America) Inc.

Background

For several years now, clinics in Great Britain have been treating migraine sufferers with a device known in North america as the Enermed, a device developed by the British engineer, Stephen Walpole. Enermed is a small, battery-powered device that emits a continuous, pulsed flow of extremely low frequency (ELF) electromagnetic energy. The device was developed after Walpole, who was subject to intense migraines himself, discovered that migraine sufferers tend to have lower than average levels of brainwave activity in the low frequency end of the electromagnetic spectrum. The Enermed device is worn close to the body and exposes the migraine sufferer to a continuous pulsed flow of energy in the deficient or low activity frequencies.

Walpole's personal experience, plus anecdotal data from several early case studies, suggested that exposure to this kind of electromagnetic energy reduced the incidence of migraines in chronic sufferers (Walpole, 1993). In 1988, a pilot study of the practical applications of electromagnetic therapy yielded similar results (Young, 1993). Young, an independent researcher from the Koestler Foundation in London, tracked a sample of 54 migraine sufferers for three months after they received one of Walpole's early versions of the Enermed device. She found that the average number of migraines reported by subjects dropped by half, from 1.2 to .6 per week, once they started wearing their devices. Pain levels and the average duration of subjects' headaches also dropped significantly. The treatment effects were immediate and enduring.

The results of Young' s study support the potential practical application of electromagnetic therapy in the treatment of migraines. However, before launching Enermed in North America, the directors of Energy Medicine Developments (North America) Inc. requested that users in Great Britain be polled to determine their perceptions of effectiveness of the most recent version of the device. The procedure and results of this study are reported below.

Research Method:

During the summer of 1994, Walpole's company mailed out one page surveys to approximately 1,200 individuals who had purchased Enermed devices from clinics in the United Kingdom in the preceding fifteen months. By mid-August, approximately 500 surveys had been returned, for a response rate of 42%. A total of 269 of the respondents had been treated for migraines; the rest had been treated for one or more of a variety of other disorders. This report addresses results for the migraine patients only.

The survey asked respondents to use a 10 point scale to indicate how they felt before and after they started wearing their Enermed devices ("1" = "perfectly well" , "10" = "extremely bad"). High scores for the migraine sample are assumed to reflect the seriousness of migraine related symptoms (nausea, light sensitivity, etc.), as well as the severity of the patients' headaches.

Over half (58%) of the respondents had pre-treatment well-being scores in the "extremely bad" range (9 or 10). We call these 155 individuals the "severe symptom" group. Just over one third (36%) had pre-treatment scores of 7 or 8; these 96 individuals constitute the "serious symptom" group. The "moderate symptom" group consists of the 14 people (5%) with pre-treatment scores at or near the midpoint of the scale (5 or 6). Four respondents had pre-treatment scores in the positive end of the scale (2 to 4) and were dropped from the analyses. This resulted in a final analysis sample of 265 moderate to severe migraine sufferers.

Research Results:

The large majority of respondents (82%) reported at least a modest improvement (two points or more) in their overall well-being after receiving the Enermed device. More striking, however, is large number of individuals who experienced dramatic improvements after treatment. In the Severe Symptom group, for example, over one fourth (28%) indicated that their migraine symptoms virtually disappeared once they started using Enermed - pain scores dropped from the very highest levels (9-10) to the very lowest (1-2) levels possible. Another 32% in this group experienced a 5 to 7 point improvement, with post-treatment scores in the "mild discomfort" range (3-4). Overall, then, fully 60% of the patients with the most debilitating symptoms prior to treatment experienced dramatic improvements after receiving the Enermed device. Another 25% reported modest improvements, and only 15% failed to improve at all.

Post-Treatment Symptom Ratings for Patients with Severe/Serious Pre-Treatment Symptoms
SEVERE
9-10) SERIOUS
(7-8) MOD
(5-6) MILD
(3-4) NEGLIGIBLE
(1-2)
SEVERE Migraine Group (n=155) 15% 8% 17% 32% 28%
SERIOUS Migraine Group (n=96) 4% 12% 15% 39% 29%



Comparable results were obtained for the 96 patients in the Serious Symptom group (those with pre-treatment scores of 7 or 8). Over two thirds (68%) of the respondents in this group reported well-being levels in the positive end of the scale after treatment, including 39% who indicated only mild discomfort after treatment and 29% who said they felt "perfectly well" once they started using Enermed. The small number of respondents (n=14) seeking treatment for only moderate symptoms render the results for this particular group somewhat unreliable; the trend, however, was similar to that observed for the more serious migraine sufferers.

Discussion and Recommendations:

The results of this study are very encouraging. Overall, almost two thirds of the respondents reported substantial improvements in their well-being after they started using Enermed. The results do not reveal how Enermed alleviates suffering, nor can this research offer clues as to why treatment failed to work for about 15% of the sample. Combined with similar findings from previous research, however, the results do attest to the promise electromagnetic therapy holds for the typical migraine patient. The strength, consistency, and apparent duration of the effect make it highly unlikely that the improvements reported by respondents simply reflect a placebo effect or retrospective bias.

Sampling error is probably the most serious concern with respect to the validity of the research. Although a response rate of 42% is considered respectable for a mail out survey, it does not eliminate the possibility that survey respondents are not representative of the population of migraine sufferers seeking treatment. Only follow-up research can establish with certainty that the success rates reported here are typical, and thus likely to be replicated.

Additional data on patient characteristics and symptom patterns would also be useful, both to further our understanding of how the Enermed device works and to fine-tune efforts to program the most effective frequencies for individual patients. Currently, Enermed devices are programmed based on the results of a brain wave activity analysis and a largely anecdotal, but expanding, body of knowledge about the frequency ranges likely to be effective for individuals with particular symptoms or onset factors. This method works very well in many, but clearly not all cases. The key to more efficient diagnosis and treatment may lie in the systematic collection and analysis of personal and medical history data.

The ideal study would also include randomized assignment to blind treatment and control groups and/or provisions for assessing the impact of withholding treatment from patients for whom it appears to be successful. These research designs are very expensive, however, and likely to be impractical outside of large, well-funded research laboratories.

In the meantime, efforts to make this novel, promising treatment available to a wider audience appear warranted.
Exposure to extremely low frequency electromagnetic radiation has already helped hundreds of migraine sufferers in Great Britain. Distribution of the Enermed in North America, combined with serious efforts to better understand when and how it is most effective, could alleviate suffering for many of the millions of migraine victims in Canada and the US.

References


Walpole, Stephen (1993). Medigen and the brain frequency analyser. International Journal of Alternative and Complementary Medicine. October, 1993.


Young, Sophie (1993). Pilot study concerning the effects of extremely low frequency electromagnetic energy on migraine (from The Koestler Foundation, London, 1988). International Journal of Alternative and Complementary Medicine. October, 1993.

About the Author

Dr. Lappin received her bachelor's degree from Colgate University and her master's degree and doctorate in psychology from Michigan State University. She spent 15 years as a research psychologist for the U.S. Army Research Institute (ARI), where she was the leader of the Special Forces research team. She authored numerous technical reports and conference papers, and was awarded the Superior Civilian Service Award for her work in 1997.

Dr. Lappin began working as a consultant to Energy Medicine Developments (North America) Inc. in 1994, and since May of 1997 has served as their research director, as well as the president of Alternative Health Care Research, Inc. Current research activities include follow-up research on migraine patients treated in Canada and coordinating the multi-site clinical trials EMD is sponsoring on the effectiveness of the Enermed as a symptomatic treatment for multiple sclerosis.



Note: The Enermed device was formerly called "Medigen" in Great Britain.

--------------------------------------------------------------------------------

NOTE:

The Enermed is a complementary therapy and is not to be regarded as a substitute for the attention of the user's doctor or medical advisor, and such attention should not be withheld on the grounds of the use of the Enermed. The Enermed is not to be used by people with a pacemaker, or those suffering from epilepsy, cancer, diabetes or with heart or kidney disease and should be removed in the case of pregnancy.

The patient must have received a diagnosis from their doctor prior to visiting an Enermed location.

Individuals with a pacemaker, suffering from epilepsy, cancer, diabetes insipidus, or heart or kidney disease will not be eligible for treatment with the Enermed.

[jmhollen]

Three month chart from PCQuote....:

[jmhollen]

bobsnook66,

Thanks for bring the matter up, I had almost forgotten about this one.

I set up the board before they actually got listed for quotation.

Hope you're doing well with it.

John

[jmhollen]

The Enermed is a battery operated, pulsed electromagnetic field generator

[bobsnook66]

gbis running like a champ today up 150%. no headache here

[Ruellit]

Global Innovative Systems, Inc. (GBIS): Negotiations Opened with Consultants Which Specialize in FDA Procedures.

Global Innovative Systems, Inc. (GBIS): Negotiations Opened with
Consultants Which Specialize in FDA Procedures.

LAS VEGAS, Mar 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- The directors of Global Innovative Systems, Inc. (OTC Bulletin Board: GBIS), a Nevada corporation, announced that the Company has entered into negotiations with a US-based consulting group which specialize in the procedures necessary for medical device applications to the Food and Drug Administration. The Company
believes that the consulting group's specific experience will supplement the existing expertise of Energy Medicine Developments management group as the Company prepares for its third, double blind, placebo controlled clinical trial into the symptomatic relief of multiple sclerosis.

The Enermed Therapy is licensed by Health Canada to provide non-invasive symptomatic relief to people with multiple sclerosis and/or migraine headaches. The effectiveness of the Enermed Therapy has been evaluated through controlled clinical trials. Additionally, a company survey mailed to Enermed patients one
to fifteen months after they received their individually programmed Enermed devices indicated that the large majority of people using the device experienced improvement in their condition.

An estimated 13 to 17 billion dollars are lost in the United States each year in direct and indirect costs associated with migraine headaches, including such items as lost wages and reduced productivity. According to a study presented at the American Academy of Neurology, approximately half of the estimated 28 million migraine sufferers in the United States have given up on conventional medical treatments, and the majority (64%) of those who do seek medical help are dissatisfied with their care. Individuals seeking relief from chronic debilitating headaches are more likely than ever to turn to alternative, non-drug therapies such as the Enermed.

It is estimated that there are 500,000 MS sufferers in the United States and up to 2 million worldwide. The National Multiple Sclerosis Society estimates that direct and indirect costs associated with MS exceed 9 billion dollars annually.
Due to the relatively low effect rate of traditional MS medications, many MS patients are looking to alternative therapies to alleviate their symptoms.

For more information on the Enermed Therapy for the symptomatic relief of multiple sclerosis and/or migraine headaches visit the Company's website at http://www.enermed.com, to schedule an appointment call 1-866 ENERMED, or for information on Investor Relations contact Yorkville Capital Partners at [phone].

Certain of these statements contained in the press release may be deemed forward-looking statements. Such statements, and other matters addressed in this press release, involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from these statements and
matters are the risks and other factors detailed, from time to time, in the Company's reports with Securities and Exchange Commissions, including, but not limited to, the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.


Muell <g>

[jmhollen]

Global Innovative Systems, Inc. Announces Share Buy Back Plan

LAS VEGAS, March 12 /PRNewswire-FirstCall/-- Global Innovative Systems, Inc. (OTC Bulletin Board: GBIS - news), a Nevada Corporation, announces today that it plans to buy back up to 20% of its 9,500,000 common shares that are in the float.

Purchases may be made from the open market at prevailing market prices. The number of shares of common stock actually purchased by the Company will depend on subsequent developments and corporate needs, and the buy back of shares may be cancelled at any time.

At current prices, we feel that our stock is undervalued, Global Innovative Systems, Inc., by reducing the size of the float, we hope to achieve a more realistic value between the stock valuation and the company's performance to date and to enhance shareholder value in the long run.

About Global Innovative Systems, Inc.

The ``Enermed Therapy' is an innovative electrode-less technology that, prior to the pilot study with MS, was used primarily to treat migraine headaches. The technology allows a trained technician to take a reading of the amplitude of the bioelectromagnetic signals emitted by individual patients. The Enermed Device, a non-invasive, pulsed electromagnetic field generator is then programmed based on each patient's own bioelectromagnetic profile. The electromagnetic energy generated by the Enermed is similar in strength to the electromagnetic field produced by the earth.

The 1997 pilot study and the more recent multi-site clinical trial of the Enermed demonstrated the Company's commitment to completing the research required for FDA approval of this therapy. A non-pharmacological treatment for the symptoms of MS would be a tremendous breakthrough for the MS community. It is estimated that 350,000 people in the United States and up to 2 million people worldwide suffer from MS. The National Multiple Sclerosis Society estimates that direct and indirect costs associated with MS exceed 9 billion dollars annually.

For more information on the Enermed Therapy for the symptomatic relief of MS and Migraine headaches visit the Company's website at www.enermed.com, to schedule an appointment call 1-866ENERMED.

SOURCE: Global Innovative Systems, Inc.

.

[jmhollen]

Global Innovative Systems, Inc. (GBIS): Negotiations Opened with Consultants Which Specialize in FDA Procedures.

LAS VEGAS, March 13 /PRNewswire-FirstCall/ -- The directors of Global Innovative Systems, Inc. (OTC Bulletin Board: GBIS - news), a Nevada corporation, announced that the Company has entered into negotiations with a US-based consulting group which specialize in the procedures necessary for medical device applications to the Food and Drug Administration. The Company believes that the consulting group's specific experience will supplement the existing expertise of Energy Medicine Developments management group as the Company prepares for its third, double blind, placebo controlled clinical trial into the symptomatic relief of multiple sclerosis.

The Enermed Therapy is licensed by Health Canada to provide non-invasive symptomatic relief to people with multiple sclerosis and/or migraine headaches. The effectiveness of the Enermed Therapy has been evaluated through controlled clinical trials. Additionally, a company survey mailed to Enermed patients one to fifteen months after they received their individually programmed Enermed devices indicated that the large majority of people using the device experienced improvement in their condition.

An estimated 13 to 17 billion dollars are lost in the United States each year in direct and indirect costs associated with migraine headaches, including such items as lost wages and reduced productivity. According to a study presented at the American Academy of Neurology, approximately half of the estimated 28 million migraine sufferers in the United States have given up on conventional medical treatments, and the majority (64%) of those who do seek medical help are dissatisfied with their care. Individuals seeking relief from chronic debilitating headaches are more likely than ever to turn to alternative, non-drug therapies such as the Enermed.

It is estimated that there are 500,000 MS sufferers in the United States and up to 2 million worldwide. The National Multiple Sclerosis Society estimates that direct and indirect costs associated with MS exceed 9 billion dollars annually. Due to the relatively low effect rate of traditional MS medications, many MS patients are looking to alternative therapies to alleviate their symptoms.

For more information on the Enermed Therapy for the symptomatic relief of multiple sclerosis and/or migraine headaches visit the Company's website at http://www.enermed.com, to schedule an appointment call 1-866 ENERMED, or for information on Investor Relations contact Yorkville Capital Partners at [phone].

SOURCE: Global Innovative Systems, Inc.

.

[Ruellit]

Global Innovative Systems, Inc. Announces Share Buy Back Plan
TUESDAY, MARCH 12, 2002 9:25 AM
- PRNewswire

LAS VEGAS, Mar 12, 2002 /PRNewswire-FirstCall via COMTEX/ -- Global
Innovative Systems, Inc. (GBIS) , a Nevada Corporation, announces today that
it plans to buy back up to 20% of its 9,500,000 common shares that are in
the float.

Purchases may be made from the open market at prevailing market prices. The
number of shares of common stock actually purchased by the Company will
depend on subsequent developments and corporate needs, and the buy back of
shares may be cancelled at any time.

At current prices, we feel that our stock is undervalued, Global Innovative
Systems, Inc., by reducing the size of the float, we hope to achieve a more
realistic value between the stock valuation and the company's performance to
date and to enhance shareholder value in the long run.

About Global Innovative Systems, Inc.

The "Enermed Therapy" is an innovative electrode-less technology that, prior
to the pilot study with MS, was used primarily to treat migraine headaches.
The technology allows a trained technician to take a reading of the
amplitude of the bioelectromagnetic signals emitted by individual patients.
The Enermed Device, a non-invasive, pulsed electromagnetic field generator
is then programmed based on each patient's own bioelectromagnetic profile.
The electromagnetic energy generated by the Enermed is similar in strength
to the electromagnetic field produced by the earth.

The 1997 pilot study and the more recent multi-site clinical trial of the
Enermed demonstrated the Company's commitment to completing the research
required for FDA approval of this therapy. A non-pharmacological treatment
for the symptoms of MS would be a tremendous breakthrough for the MS
community. It is estimated that 350,000 people in the United States and up
to 2 million people worldwide suffer from MS. The National Multiple
Sclerosis Society estimates that direct and indirect costs associated with
MS exceed 9 billion dollars annually.

For more information on the Enermed Therapy for the symptomatic relief of MS
and Migraine headaches visit the Company's website at www.enermed.com, to
schedule an appointment call 1-866ENERMED.

Certain of these statements contained in the press release may be deemed
forward-looking statements. Such statements, and other matters addressed in
this press release, involve a number of risks and uncertainties. Among the
factors that could cause actual results to differ materially from these
statements and matters are the risks and other factors detailed, from time
to time, in the Company's reports with Securities and Exchange Commissions,
including, but not limited to, the Company's Annual Reports on Form 10-K and
its Quarterly Reports on Form 10-Q.

Anyone interested in gaining more info on GBIS can cal Jeff Sundar at 1-866-885-5111 (toll free)
Muell <g>

[jmhollen]

Global Innovative Systems, Inc. Announces Filing of the 8K Reporting
The Acquisition of Energy Medicine Developments Corp., and the Addition
of The ENERMED Founders to the Board of Directors Global
Innovative Systems, Inc. (GBIS) Las Vegas, Nevada US

LAS VEGAS, Feb 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Global Innovative
Systems, Inc (OTC Bulletin Board: GBIS) -- The Company is pleased to announce
that it has filed the 8K reflecting the acquisition of Energy Medicine
Developments Corp. Energy Medicine Developments owns the intellectual property
and technology of the pulsed electromagnetic ENERMED device, the supporting
bioelectromagnetic analysis equipment, and the worldwide rights to manufacture
and market this equipment.

The Enermed Therapy is currently licensed by Health Canada to provide non-
invasive symptomatic relief to people with multiple sclerosis and/or migraine
headaches. The effectiveness of the Enermed Therapy has been evaluated through
controlled clinical trials. Additionally a company survey mailed to Enermed
patients one to fifteen months after they received their individually programmed
Enermed devices indicated that the large majority of people using the device
experienced improvement in their condition.

At this time the Company is also pleased to announce that that the two founding
principals of Energy Medicine Developments doing business as ENERMED have agreed
to join its Board of Directors. After incorporating Energy Medicine Developments
in 1994 the principals have overseen the opening of the initial treatment centre
in Vancouver, British Columbia in 1995 and a second treatment centre in Toronto,
Ontario in 1997. Both have been active in the Company's growth and will continue
to oversee the ongoing growth of the business in North America and
internationally.

Robert Michael Fletcher, CGA; educated in Great Britain, he worked in England
and on contract in Bermuda, before he emigrated to Canada in 1972. He was
employed as Senior Vice President Canada by a US based, multi national financial
organization which was responsible for providing corporate finance and
consulting advice. He incorporated his own specialized corporate financial
service company in 1983. He became a consultant to the health care industry in
the early 1990's and together with Fraser Wilson Lawrie was responsible for the
incorporation of Energy Medicine Developments in 1994. He has been actively
involved with the Company since its incorporation. He received his Certified
General Accountant designation in 1985.

Fraser Wilson Lawrie, M.S.; educated in Scotland, he emigrated to Canada in 1979
and pursued a career in the pharmaceutical industry. Whilst working as a
consultant to the health care industry he became interested in pulsed
electromagnetic therapy in the early 1990's culminating in the establishment of
Energy Medicine Developments in 1994. He has been actively involved with the
Company since its incorporation. He has a Masters Degree in Health Science.

The Company is also pleased to confirm Energy Medicine Developments Medical
Advisory Board chaired by Dr. Martha Lappin and including Robert Fabiny, MD,
Ph.D.; Eric Kramer, MD; and Todd Richards, Ph.D. as announced December 4th,
2001.

For more information on the Enermed Therapy for the symptomatic relief of MS and
Migraine headaches visit the Company's website at www.enermed.com or, to
schedule an appointment for the Enermed Therapy call 1-866-ENERMED. For
information on Investor Relations, contact Yorkville Capital Partners, LLC at
[phone].

SOURCE Global Innovative Systems, Inc.

CONTACT:
Investor Relations - Jason Cooper of Yorkville
Capital Partners, LLC, [phone]

.